Title :

Cardiovascular drugs and metformin drug dosage according to renal function in non-institutionalized elderly patients

Author(s) :

Becquemont, Laurent [Auteur]
Bauduceau, Bernard [Auteur]
Benattar-Zibi, Linda [Auteur]
Al-Salameh, Abdallah [Auteur]
Berrut, Gilles [Auteur]
Bertin, Philippe [Auteur]
Bucher, Sophie [Auteur]
Corruble, Emmanuelle [Auteur]
Danchin, Nicolas [Auteur]
Derumeaux, Genevieve [Auteur]
Doucet, Jean [Auteur]
Falissard, Bruno [Auteur]
Forette, Françoise [Auteur]
Hanon, Olivier [Auteur]
Pasquier, Florence [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Pinget, Michel [Auteur]
Ourabah, Rissane [Auteur]
Piedvache, Céline [Auteur]

Journal title :

Basic & clinical pharmacology & toxicology

Abbreviated title :

Basic Clin. Pharmacol. Toxicol.

Volume number :

118

Pages :

468-473

Publication date :

2016-06-01

ISSN :

1742-7835

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Adaptation of drug dosage to kidney function is a common problem in general practice. The aim was to describe adaptation of cardiovascular drugs and metformin according to renal function and its association with mortality ...
Show more >Adaptation of drug dosage to kidney function is a common problem in general practice. The aim was to describe adaptation of cardiovascular drugs and metformin according to renal function and its association with mortality with regard to metformin in a cohort of elderly patients. This was an ancillary study to the S.AGES cohort made up of patients over 65 years of age managed by their general practitioner under real-life conditions and followed up prospectively for 3 years. The medications studied were digoxin, spironolactone and metformin. Adaptation of their daily dose according to renal function (eGFR according to CKD/EPI) was compared to that recommended in the summaries of product characteristics (SPCs) or international scientific societies (ISS). A total of 900 patients were included, including 588 on metformin. At baseline, dose adjustment according to renal function was 100% and 87.6% (95% CI: 82.6-92.6) for patients on digoxin and spironolactone respectively. For metformin, only 71.3% (95% CI: 67.6-74.9) or 78.1% (95% CI: 74.7-81.4) of patients had their dosage adapted at inclusion according to their renal function depending on whether the SPCs or ISS recommendations were considered. During the 3-year follow-up period, 42/588 patients died (none from lactic acidosis). At inclusion, a metformin dosage not adapted for renal function according to ISS was not associated with an increase in all-cause mortality (OR 1.7; 95% CI 0.6-5.0, p = 0.32). In conclusion, approximately one-quarter of elderly patients treated with metformin do not have their dosage adapted for renal function according to ISS although there is no increase in mortality after follow-up for 3 years.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:29:17Z